

# Arun Rajan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8510454/publications.pdf>

Version: 2024-02-01

55  
papers

3,016  
citations

279798

23  
h-index

175258

52  
g-index

57  
all docs

57  
docs citations

57  
times ranked

4060  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , 2018, 33, 244-258.e10.	16.8	270
2	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	10.7	261
3	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 599-610.	10.7	257
4	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	10.7	240
5	Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 2052-2059.	1.6	174
6	A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2344-2351.	7.0	151
7	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. <i>Journal of Thoracic Oncology</i> , 2022, 17, 200-213.	1.1	124
8	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 6831-6839.	7.0	123
9	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1594-1602.	1.6	122
10	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 191-200.	10.7	111
11	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , 2014, 4, 7336.	3.3	109
12	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.9	97
13	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
14	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. <i>Clinical Cancer Research</i> , 2014, 20, 5392-5402.	7.0	83
15	Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 179-193.	1.1	82
16	High mesothelin expression in advanced lung adenocarcinoma is associated with <i>KRAS</i> mutations and a poor prognosis. <i>Oncotarget</i> , 2015, 6, 11694-11703.	1.8	66
17	State of the Art of Genetic Alterations in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, S131-S136.	1.1	60
18	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 8034-8034.	1.6	59

#	ARTICLE	IF	CITATIONS
19	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	3.3	49
20	Treatment of Advanced Thymoma and Thymic Carcinoma. <i>Current Treatment Options in Oncology</i> , 2008, 9, 277-287.	3.0	38
21	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. <i>Nature Communications</i> , 2022, 13, 2023.	12.8	36
22	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
23	Chemotherapy for Thymic Tumors: Induction, Consolidation, Palliation. <i>Thoracic Surgery Clinics</i> , 2011, 21, 107-114.	1.0	32
24	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	2.8	32
25	Targeted Therapy for Advanced Thymic Tumors. <i>Journal of Thoracic Oncology</i> , 2010, 5, S361-S364.	1.1	24
26	Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group. <i>Journal of Thoracic Oncology</i> , 2017, 12, 745-751.	1.1	23
27	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 403-5.	2.8	21
28	Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8519-8519.	1.6	20
29	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an exceptional responder lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001263.	1.2	18
30	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. <i>Lung Cancer</i> , 2016, 101, 104-110.	2.0	18
31	Thymic Carcinomas – A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. <i>Journal of Thoracic Oncology</i> , 2022, 17, 637-650.	1.1	18
32	Hepatoid adenocarcinoma of the lung metastasizing to the tonsil. <i>Molecular and Clinical Oncology</i> , 2017, 6, 705-707.	1.0	17
33	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
34	<i>EGFR</i> Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , 2016, 2, 259-267.	0.5	15
35	Deciphering the biology of thymic epithelial tumors. <i>Mediastinum</i> , 2019, 3, 36-36.	1.1	15
36	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. <i>Oncology Letters</i> , 2015, 10, 1155-1158.	1.8	12
38	Acute Autoimmune Hepatitis, Myositis, and Myasthenic Crisis in a Patient with Thymoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, e87-e88.	1.1	10
39	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 36-48.	0.6	8
40	Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. <i>Translational Lung Cancer Research</i> , 2017, 6, 588-599.	2.8	7
41	Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100229.	1.1	7
42	Avelumab (anti-PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 9090-9090.	1.6	7
43	Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword. <i>Cancers</i> , 2022, 14, 2060.	3.7	7
44	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019, 14, e0212097.	2.5	6
45	Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA) <sub>n</sub> Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 896.	4.1	6
46	The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review. <i>Mediastinum</i> , 2021, 5, 23-23.	1.1	6
47	Immunotherapy for Thymic Cancers: A Convuluted Path Toward a Cherished Goal. <i>Journal of Thoracic Oncology</i> , 2021, 16, 352-354.	1.1	4
48	Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib. <i>Journal of Clinical Oncology</i> , 2017, 35, e20545-e20545.	1.6	4
49	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, e353-e356.	3.7	2
50	Novel Treatments for Thymoma and Thymic Carcinoma. <i>Frontiers in Oncology</i> , 2015, 5, 267.	2.8	1
51	Consolidative local therapy in oligometastatic patients. <i>Lancet Oncology</i> , The, 2017, 18, e61.	10.7	1
52	Thymic Hyperplasia after Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. <i>Journal of Thoracic Oncology</i> , 2017, 12, e29-e32.	1.1	1
53	Uncommon efforts for an uncommon tumor: the case for development of newer systemic therapies for advanced thymic epithelial tumors. <i>Mediastinum</i> , 2018, 2, 12-12.	1.1	1
54	A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9108-TPS9108.	1.6	1

#	ARTICLE	IF	CITATIONS
55	EGFR mutations in Latinos from the United States and Latin America.. Journal of Clinical Oncology, 2015, 33, 8070-8070.	1.6	0